Keywords: mapreg, spinal, injury, drug, gets, od, status

Mapreg spinal injury drug gets OD status

Article | 24 March 2008

Print This

Mapreg, a French biotechnology company specialized in the development of novel drugs for the treatment of central nervous system diseases, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in